Trust Investment Advisors continued to hold its position in Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 8,155 shares of the medical research company’s stock at the end of the second quarter. Amgen accounts for approximately 1.5% of Trust Investment Advisors’ investment portfolio, making the stock its 20th largest position. Trust Investment Advisors’ holdings in Amgen were worth $1,405,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Camelot Portfolios LLC purchased a new position in shares of Amgen during the 1st quarter valued at $1,429,000. PGGM Investments lifted its holdings in shares of Amgen by 2.3% during the 2nd quarter. PGGM Investments now owns 670,936 shares of the medical research company’s stock worth $115,555,000 after acquiring an additional 15,059 shares during the last quarter. Shelton Capital Management lifted its holdings in shares of Amgen by 82.7% during the 1st quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock worth $17,883,000 after acquiring an additional 49,354 shares during the last quarter. Greylin Investment Mangement Inc. lifted its holdings in shares of Amgen by 466.9% during the 2nd quarter. Greylin Investment Mangement Inc. now owns 14,030 shares of the medical research company’s stock worth $2,416,000 after acquiring an additional 11,555 shares during the last quarter. Finally, Kelman Lazarov Inc. lifted its holdings in shares of Amgen by 8.2% during the 2nd quarter. Kelman Lazarov Inc. now owns 1,580 shares of the medical research company’s stock worth $272,000 after acquiring an additional 120 shares during the last quarter. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Amgen Inc. (AMGN) opened at 183.01 on Monday. The stock’s 50 day moving average is $183.93 and its 200 day moving average is $170.98. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $191.10. The company has a market capitalization of $133.54 billion, a P/E ratio of 16.67 and a beta of 1.36.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business’s revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the business earned $2.84 EPS. On average, equities research analysts expect that Amgen Inc. will post $12.58 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Trust Investment Advisors Has $1,405,000 Stake in Amgen Inc. (AMGN)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/trust-investment-advisors-has-1405000-stake-in-amgen-inc-amgn/1633583.html.

In other news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.19% of the stock is currently owned by company insiders.

A number of analysts have recently issued reports on the stock. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $203.00 price objective on shares of Amgen in a report on Friday, October 6th. Mizuho reaffirmed a “buy” rating and set a $198.00 price objective on shares of Amgen in a report on Friday, October 6th. Barclays PLC lifted their price objective on shares of Amgen from $180.00 to $190.00 and gave the stock an “equal weight” rating in a report on Friday. Jefferies Group LLC reaffirmed a “buy” rating and set a $195.00 price objective on shares of Amgen in a report on Tuesday, July 11th. Finally, Credit Suisse Group reaffirmed a “neutral” rating and set a $186.00 price objective (up from $177.00) on shares of Amgen in a report on Friday, September 29th. Eleven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. Amgen currently has a consensus rating of “Buy” and an average target price of $189.99.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.